Bioinspired Polydopamine-Coated Hemoglobin as Potential Oxygen Carrier with Antioxidant Properties.
Oxidative side reaction is one of the major factors hindering the development of hemoglobin-based oxygen carriers (HBOCs). To avoid the oxidative toxicity, we designed and synthesized polydopamine-coated hemoglobin (Hb-PDA) nanoparticles via simple one-step assemblage without any toxic reagent. Hb-PDA nanoparticles showed oxidative protection of Hb by inhibiting the generation of methemoglobin (MetHb) and ferryl (Fe IV) Hb, as well as excellent antioxidant properties by scavenging free radicals and reactive oxygen species (ROS). Interestingly, the scavenging rate of Hb-PDA nanoparticles for ABTS+radical is at most 89%, while for DPPH radical it reaches 49%. In addition, Hb-PDA efficiently reduced the intracellular H2O2-induced ROS generation. Moreover, Hb-PDA nanoparticles exhibited high oxygen affinity, low effect on blood constituents, and low cytotoxicity. The results indicate that polydopamine-coated hemoglobin might be a promising approach for constructing novel oxygen carriers with the capacity to reduce oxidative side reaction.
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Quan
Q
Wang
National Center for Nanoscience and Technology , 100190 Beijing, People's Republic of China.|Beijing Key Laboratory of Ionic Liquids Clean Process, Key Laboratory of Green Process and Engineering, Institute of Process Engineering, Chinese Academy of Sciences , 100190 Beijing, People's Republic of China.
Ruirui
R
Zhang
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Mingzi
M
Lu
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Guoxing
G
You
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Ying
Y
Wang
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Gan
G
Chen
National Center for Nanoscience and Technology , 100190 Beijing, People's Republic of China.
Caiyan
C
Zhao
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Zhen
Z
Wang
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Xiang
X
Song
National Center for Nanoscience and Technology , 100190 Beijing, People's Republic of China.
Yan
0000-0001-8508-7077
Y
Wu
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Lian
L
Zhao
Beijing Institute of Transfusion Medicine, Beijing Key Laboratory of Blood Safety and Supply Technologies, 100039 Beijing, People's Republic of China.
Hong
0000-0003-2987-7781
H
Zhou
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000737:chemistry; D001802:Blood Substitutes; D002417:Cattle; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003432:Cross-Linking Reagents / Q000737:chemistry; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D006454:Hemoglobins / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D006461:Hemolysis / Q000187:drug effects; D061307:Human Umbilical Vein Endothelial Cells; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D053758:Nanoparticles / Q000737:chemistry; D010100:Oxygen / Q000737:chemistry*; D010851:Picrates / Q000737:chemistry; D010974:Platelet Aggregation / Q000187:drug effects; D011108:Polymers / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology*; D017208:Rats, Wistar; D017382:Reactive Oxygen Species / Q000378:metabolism; D017550:Spectroscopy, Fourier Transform Infrared
D000975:Antioxidants; D001672:Biocompatible Materials; D001713:Biphenyl Compounds; D001802:Blood Substitutes; D003432:Cross-Linking Reagents; D006454:Hemoglobins; D007211:Indoles; D010851:Picrates; D011108:Polymers; D017382:Reactive Oxygen Species; C568283:polydopamine; C004931:1,1-diphenyl-2-picrylhydrazyl; D010100:Oxygen